“How New Drugs & Stem Cell Treatments Are Saving Hearts and Kidneys”
In an exciting development, scientists in Shanghai have made a groundbreaking breakthrough — successfully curing type 2 diabetes through stem cell-derived islet transplantation. This revolutionary therapy opens the door to a diabetes-free future for millions worldwide. But the advances don’t stop there — recent innovations in diabetes management, especially in cardiovascular and renal care, are making waves.
A Breakthrough Cure
“Researchers studied this 59-year-old man with 25 years of type 2 diabetes. After a kidney transplant in 2017, his pancreas stopped working well, so he needed insulin shots daily. To help, Dr. Yin Hao’s team used a new stem cell treatment. They took the patient’s own stem cells, turned them into functional pancreas cells, and then implanted these cells into him.”
The 59-year-old patient with type 2 diabetes and kidney complications was treated with stem cell-derived islet cells. These cells were able to restore the patient’s insulin production, leading to normal blood sugar levels — without the need for daily insulin injections or medications! After just 11 weeks, the patient achieved complete insulin independence and showed improved kidney function.
In July 2021, the patient received an autologous islet cell transplant. Remarkably, insulin independence was achieved just 11 weeks after the procedure. Diabetes medications were gradually reduced and stopped entirely within a year.
Subsequent follow-up showed that pancreatic function was restored, with no need for insulin or oral diabetes medications. Kidney function remained normal, indicating a potential long-term cure for both type 2 diabetes and complications from the original kidney transplant.
Innovations in Cardiovascular & Renal Outcomes
“Clinical trials show that SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) not only help control blood sugar but also better protect the heart and kidneys. These treatments are important for managing type 2 diabetes (T2DM) and offer more options for patients.”
“Managing type 2 diabetes (T2DM) has changed from just focusing on blood sugar levels to a more personalized approach. Now, treatment considers each patient’s unique needs, including blood sugar and weight goals, risk of low blood sugar, and preventing heart and kidney problems. It also takes into account how easy it is to access and afford medications. This new method helps improve the overall quality of life for people with T2DM.”
The benefits of SGLT2 inhibitors (SGLT2i) go far beyond blood sugar control. Large trials like EMPA-REG OUTCOME and CANVAS have demonstrated that SGLT2i reduces the risk of major cardiovascular events (MACE) such as heart failure hospitalizations and the progression of kidney disease. These findings have led to new guidelines emphasizing cardiovascular and renal health in diabetes management.
Heart Failure Trials
In heart failure studies like DAPA-HF and EMPEROR-Reduced, SGLT2i drugs showed a profound effect in reducing heart failure risks — regardless of the presence of diabetes. The EMPEROR-Preserved trial found that empagliflozin reduced cardiovascular death or hospitalization for heart failure in patients with a preserved ejection fraction, further solidifying its role in heart health.
The GLP-1 Receptor Agonists: A Game-Changer
GLP-1 receptor agonists (GLP-1 RA) not only improve glucose control but have demonstrated remarkable cardiovascular benefits in various studies. The LEADER trial with liraglutide, SUSTAIN-6 with semaglutide, and REWIND with dulaglutide all showed reduced risks of cardiovascular death, stroke, and heart attack.
More impressively, GLP-1 RA drugs are also showing significant renal protection benefits. Studies like LEADER and REWIND show reductions in the progression of diabetic kidney disease, further enhancing the quality of life for patients with type 2 diabetes.
Stem cell treatments offer a promising new avenue for managing the disease by regenerating insulin-producing cells, while innovative drugs like SGLT2 inhibitors and GLP-1 receptor agonists provide crucial benefits beyond blood sugar control, including improved heart and kidney health. Together, these advancements are expanding treatment options and hold the potential to greatly enhance patient outcomes and quality of life.
Feeling Good At Any Age- The One-Stop Rejuvenation Center
Experience Wellness and Rejuvenation at Every Stage of Life — Welcome to the FGAAA Clinic, your ultimate destination for revitalization and health enhancement.
Credit Sources:
[2] Watts, M. (2023, December 14). Type 2 Diabetes. Diabetes.co.uk. https://www.diabetes.co.uk/type2-diabetes.html
[3] Chong K, Chang JK-J, Chuang L-M.Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. Kaohsiung J Med Sci. 2024;40(3):212–20. https://doi.org/10.1002/kjm2.12800220
[4] Wu, J., Li, T., Guo, M. et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discov 10, 45 (2024). https://doi.org/10.1038/s41421-024-00662-3